TickerTalks
Browse all tickers →
TickerTalks›$TENX
TETENX

Tenax Therapeutics, Inc.

$TENX·$356M·Biotechnology·Healthcare
$1.80-1.6%1Y-69.7%
Mentions · last 7 days
2026-08-07: 38 posts2026-08-08: 15 posts2026-08-09: 25 posts2026-08-10: 381 posts2026-08-11: 134 posts2026-08-12: 41 posts2026-08-13: 28 posts662+3%
Price updated 1d ago·X counts updated 2d ago
TETENX
$TENXTenax Therapeutics, Inc.
$1.80-1.64%662 posts+3%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $TENX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Broken storySelling offAI verdict · as of 2026-08-15

Falling on heavy selling — points lower unless it turns around.

Tenax's Phase 3 pulmonary-hypertension trial just failed — the equity is now essentially a cash-shell trading below net cash.

Tenax Therapeutics is a small biotech that was betting the company on TNX-103 (a levosimendan formulation) for pulmonary hypertension associated with heart failure with preserved ejection fraction. The Phase 3 LEVEL trial results announced August 10 missed the primary endpoint, and the stock collapsed 88-89% in a single day.

  • Primary endpoint failure is what matters: the drug missed on the main outcome and no subgroup slice changes what the label can say — subgroups can support a next-trial rationale but don't rescue this filing.
  • The equity is now essentially a cash-shell: $118M cash, zero debt, ~$356M market cap — analysts point to a $2.06 net-cash floor vs current $1.80, so mean-reversion math technically applies.
  • Securities investigations already opened: Levi & Korsinsky and SueWallSt notices this week — litigation overhang stacks on the trial-failure drag.
  • Structural signals are extreme: 2.7% of the 52-week range, -85% below both 50-day and 200-day MAs, 22% of float traded in one window — a broken-story chart, not a slow decline.

What resolves this either way is a specific decision from management: either an announcement to return capital / wind down (which would let the cash-floor thesis print), or a new trial design that the FDA endorses (which restarts the clinical story from a much smaller base). The default path is continued drift toward net cash unless one of those decisions gets made.

Agrees with X sentimentAgrees with the X bearish read that the trial failure is the whole story — subgroup data doesn't rescue a missed primary endpoint. The contrarian cash-floor argument is technically valid but requires management to make a specific capital-return decision to actually realize.

What to watch: A management announcement on next steps — capital return / wind-down (which lets the $2.06 cash-floor thesis print) or a new FDA-endorsed trial design (restart from smaller base). Absent either, drift toward net cash continues.

On the calendar: 2026-11-11 — Q3 earnings

binary event failedlitigation overhang

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bearish sentiment76 posts analyzed · as of 2026-08-14

Tenex Therapeutics chatter is defined by the -88 to -89% single-day collapse after its cardiac drug missed the primary endpoint in a late-stage trial. Posters are meme-mocking the wreckage while contrarian value-focused traders are running the balance-sheet math ($118M cash, zero debt, -$33M enterprise value, mid-$1.30s vs a $2.06 net-cash floor) as a potential mean-reversion play. Some Shkreli-linked defenders argue the last trial was corrupted by COVID and the failed readout doesn't kill the drug. But the dominant tone is 'binary went the wrong way.'

Read the AI verdict + X sentiment for $TENX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage cardiovascular pharma developing levosimendan for heart failure and other acute cardiac conditions in the US and Canada.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $TENX.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+44.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-8.9How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-60.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-13.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-61.5%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 31, 2026$-0.35$-0.38+8.2%
Q1 2026May 12, 2026$-0.35$-0.40+12.5%
Q4 2025Mar 10, 2026$-0.38$-1.26+69.8%
Q3 2025Nov 12, 2025$-0.40$-1.33+69.9%
Next earningsWed, Nov 11·consensus EPS $-0.38

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$0———$-0.35$-14.2M
Q1 FY26$0———$-0.35$-9.3M
Q4 FY25$0———$-0.39$-13.4M
Q3 FY25$0———$-0.40$-9.2M

Forward consensus

5-year forecast · up to 9 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$4.2M$4.2M – $4.2M-$1.77-$1.90 – -$1.609
FY27$12.9M$12.9M – $12.9M-$1.90-$2.08 – -$1.649
FY28$47.7M$47.7M – $47.7M-$1.46-$2.58 – $2.279
FY29$151.8M$151.8M – $151.8M-$1.17-$1.17 – -$1.174
FY30$305.8M$305.8M – $305.8M$0.17$0.17 – $0.174

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.3%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-85.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-85.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 26.5M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today21.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.935-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 2 other (1 exempt · 1 award) in window

See when $TENX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13D/AActivist amendmentJul 31SC 13D/A
AI summary

is deemed to own in the aggregate and on a beneficial ownersh amended its 13D filing disclosing a beneficial ownership position of 4.32% in TENX (TENX) as of 2026-07-31. This is a material ownership disclosure indicating significant shareholder interest that may signal activist or strategic intent. Investors should monitor for further 13D amendments, which could indicate evolving positions or demands on management.

8-KMaterial agreementJun 308-K — Item 1.01: Material agreement
AI summary

Tenax Therapeutics, Inc. (TENX) entered into Supply Agreement As previously disclosed, pursuant to the License Agreement (as define with a counterparty on 2026-06-30, involving undisclosed consideration. closed, pursuant to the License Agreement (as defined below) between Tenax Thera. This is a material definitive agreement (Item 1.01) requiring immediate disclosure under SEC rules. Investors should review the agreement terms for financial obligations, dilution, or strategic implications.

8-KOfficer or director changeJun 298-K — Item 5.02: Officer or director change · Item 8.01: Other event
AI summary

Tenax Therapeutics, Inc. (TENX) disclosed an officer or director change (Item 5.02) on 2026-06-29. Also disclosed: Item 8.01. Details: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Executive transitions are administrative disclosures; materiality depends on the seniority of the affected position. No new financial terms were disclosed in this filing.

8-KShareholder voteJun 48-K — Item 5.07: Shareholder vote
3New insider — initial holdingsMay 133
8-KOfficer or director changeApr 228-K — Item 5.02: Officer or director change · Item 8.01: Other event
S-3Shelf registrationMar 24S-3
SC 13DActivist position (5%+)Mar 10SC 13D
+ 43 other (28 13Gs · 3 earnings 8-Ks · 2 routine 8-Ks · 2 10-Qs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX)gurufocus.com·2d agoTENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX)businesswire.com·2d agoTENX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Tenax Therapeuticsprnewswire.com·2d agoTenax Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Tenax Therapeutics (TENX)prnewswire.com·3d agoTenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Casemarketbeat.com·5d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ABCL$CAPR$ALLO$NWBO$AURA$SION$IBRX$SLS
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport